CD44+/CD24-/low cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome

被引:220
作者
Idowu, Michael O. [1 ]
Kmieciak, Maciej [2 ]
Dumur, Catherine
Burton, Regina S. [3 ]
Grimes, Margaret M.
Powers, Celeste N.
Manjili, Masoud H. [2 ]
机构
[1] Virginia Commonwealth Univ, Med Coll Virginia, Dept Pathol, Med Ctr, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Dept Microbiol & Immunol,Goodwin Res Lab, Richmond, VA 23298 USA
[3] APMC, Pathol Lab, Lake Charles, LA 70601 USA
关键词
Stem cell phenotype; Breast cancer; Triple negative; Recurrence; STEM-CELLS; MAMMARY-CARCINOMA; EXPRESSION; RESISTANCE; THERAPY; SELECTION; SURVIVAL; ANTIGEN; RELAPSE;
D O I
10.1016/j.humpath.2011.05.005
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Women classified as having triple-negative tumors have a poor prognosis. The importance of CD44(+)/CD24(-/low) (stem/progenitor cell-phenotype) in breast cancer patients has also been appreciated. However, correlation between triple negativity and CD44(+)/CD24(-/low) with tumor recurrence remains elusive. In the present study, we evaluated tumor specimens of 50 breast cancer patients with known hormone receptor status for whom we had follow-up information and outcome data available, and performed immunohistochemistry analysis to determine CD44 and CD24 expression. Gene expression arrays were also independently performed on 52 breast cancer specimens with banked frozen tissue. Lastly, we used FVBN202 transgenic mouse model of breast carcinoma and determined the hormone receptor status, the proportion of CD44(+)/CD24(-/low) breast cancer stem-like cells, and the behavior of the tumor. We determined that patients with triple-negative tumors had significantly higher incidence of recurrence or distant metastasis associated with increased frequency of breast cancer stem cell phenotypes compared with those with non-triple-negative tumors. Preclinical studies in FVBN202 transgenic mice confirmed these findings by showing that relapsed tumors were triple negative and had significantly higher frequency of breast cancer stem cells compared with their related primary tumors. Unlike non-triple-negative primary tumors, relapsed triple-negative tumors were tumorigenic at low doses when inoculated into FVBN202 transgenic mice. These findings suggest that CD44(+)/CD24(-/low) breast cancer stem-like cells play an important role in the clinical behavior of triple-negative breast cancer and that development of therapeutic targets directed to breast cancer stem-like cells may lead to reduction in the aggressiveness of triple-negative breast cancers. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:364 / 373
页数:10
相关论文
共 40 条
[1]  
Abraham BK, 2005, CLIN CANCER RES, V11, P1154
[2]   Therapeutic implications of cancer stem cells [J].
Al-Hajj, M ;
Becker, MW ;
Wichal, M ;
Weissman, I ;
Clarke, MF .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2004, 14 (01) :43-47
[3]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[4]  
[Anonymous], Cancer Facts & Figures
[5]   Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer [J].
Bedard, Philippe L. ;
de Azambuja, Evandro ;
Cardoso, Fatima .
CURRENT CANCER DRUG TARGETS, 2009, 9 (02) :148-162
[6]   Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases [J].
Brekelmans, C. T. M. ;
Tilanus-Linthorst, M. M. A. ;
Seynaeve, C. ;
Van der Ouweland, A. ;
Menke-Pluymers, M. B. E. ;
Bartels, C. C. M. ;
Kriege, M. ;
van Geel, A. N. ;
Burger, C. W. ;
Eggermont, A. M. M. ;
Meijers-Heijboer, H. ;
Klijn, J. G. M. .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (05) :867-876
[7]   MUTATION SELECTION AND NATURAL-HISTORY OF CANCER [J].
CAIRNS, J .
NATURE, 1975, 255 (5505) :197-200
[8]   Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics [J].
Calcagno, Anna Maria ;
Salcido, Crystal D. ;
Gillet, Jean-Pierre ;
Wu, Chung-Pu ;
Fostel, Jennifer M. ;
Mumau, Melanie D. ;
Gottesman, Michael M. ;
Varticovski, Lyuba ;
Ambudkar, Suresh V. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (21) :1637-1652
[9]   Breast tumor heterogeneity [J].
Campbell, Lauren L. ;
Polyak, Kornelia .
CELL CYCLE, 2007, 6 (19) :2332-2338
[10]   Evaluation of quality-control criteria for microarray gene expression analysis [J].
Dumur, CI ;
Nasim, S ;
Best, IM ;
Archer, KJ ;
Ladd, AC ;
Mas, VR ;
Wilkinson, DS ;
Garrett, CT ;
Ferreira-Gonzales, A .
CLINICAL CHEMISTRY, 2004, 50 (11) :1994-2002